A listed regenerative medical devices company has secured emergency funding to make November payroll and remain solvent.

Tissue Regenix Group plc secured an emergency overdraft of $500,000 from MidCap, its existing lender.

“The company remains in dialogue with its major shareholders with respect to its short- and medium-term funding requirement and expects to provide a further update and post a circular to shareholders later this week,” it said.